European Dermatology Forum recommends Leo Pharma drug in line with other biologics

The guiding dermatological organization has put Leo Pharma’s eczema drug, Adtralza, in the same class as other biologics. Recently, England and Wales differed in opinion when recommending it as a second-line treatment.
Photo: Leo Pharma / PR
Photo: Leo Pharma / PR
by christian bundgaard, translated by daniel pedersen

Over the summer, Leo Pharma can celebrate something of a milestone for its newest drug, Adtralza.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading